Back to home

Posts from "Issue1" tag

Categorizing “Chemo”

Tyler Redelico, PharmD, BCOP & Christina Zelasko, PharmD, BCPS Tyler Redelico, PharmD, BCOP & Christina Zelasko, PharmD, BCPS

Both health care professionals and patients regularly refer to systemic oncology treatments as “chemo”, although every month this term becomes less representative. Some medications clearly fit into certain categories: cisplatin & methotrexate (traditional chemotherapy), imatinib & ...

Read more

Engaging Specialty Pharmacies to Help Patients Cover the Cost of Therapy

Ana Begley Ana Begley

According to recent studies, nearly 1 in 4 adults in the United States who are taking prescription medications, expressed difficulty affording their prescription drugs. After a large spike in costs in 2014, prescription drug costs are expected to represent about 10% of U.S. healthcare costs over ...

Read more

Serving as Team Lead in a Quality Improvement Project

Natalie Halladay, MS, RN, FNP-BC, AOCNP® Natalie Halladay, MS, RN, FNP-BC, AOCNP®

Quality Improvement (QI) in the healthcare setting has evolved in recent years to improve outcomes in clinical practice.1 In 2010, the American Society of Clinical Oncology (ASCO) implemented the Quality Oncology Practice Initiative (QOPI®) Certification program to evaluate practice performance ...

Read more

Erdafitinib for the Treatment of Urothelial Carcinoma

Donald C Moore Donald C Moore

Erdafitinib (Balversa®, Janssen Products, LP) is a novel fibroblast growth factor receptor (FGFR) inhibitor recently approved by the FDA for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with a susceptible FGFR3 or FGFR2 genetic alteration who have ...

Read more

Enfortumab vedotin-ejfv (PADCEV)

Grashma Vadakkel, PharmD Grashma Vadakkel, PharmD

Bladder cancer is the sixth most common cancer in the United States. Patients with locally advanced or metastatic disease have poor long-term survival, especially those who have progressed after chemotherapy and immunotherapy. A new agent, enfortumab vedotin-ejfv (PADCEV, Astellas Pharma US, Inc.), ...

Read more

HPV-Associated head and neck cancer: Racial Disparities in Outcomes

Faith Mutale, MSN, CRNP Faith Mutale, MSN, CRNP

Although risk factors for squamous-cell cancer of the head and neck (SCCHN) have been identified (e.g., tobacco use, alcohol use, human papilloma virus [HPV] infection), the impact of social determinants of health (SDH) in patients with SCCHN has been poorly characterized. Moreover, ...

Read more